The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder

Ute Kessler, Arne E Vaaler, Helle Schøyen, Ketil J Oedegaard, Per Bergsholm, Ole A Andreassen, Ulrik F Malt, Gunnar Morken, Ute Kessler, Arne E Vaaler, Helle Schøyen, Ketil J Oedegaard, Per Bergsholm, Ole A Andreassen, Ulrik F Malt, Gunnar Morken

Abstract

Background: The treatment of depressive phases of bipolar disorder is challenging. The effects of the commonly used antidepressants in bipolar depression are questionable. Electroconvulsive therapy is generally considered to be the most effective treatment even if there are no randomized controlled trials of electroconvulsive therapy in bipolar depression. The safety of electroconvulsive therapy is well documented, but there are some controversies as to the cognitive side effects. The aim of this study is to compare the effects and side effects of electroconvulsive therapy to pharmacological treatment in treatment resistant bipolar depression. Cognitive changes and quality of life during the treatment will be assessed.

Methods/design: A prospective, randomised controlled, multi-centre six- week acute treatment trial with seven clinical assessments. Follow up visit at 26 weeks or until remission (max 52 weeks). A neuropsychological test battery designed to be sensitive to changes in cognitive function will be used.

Setting: Nine study centres across Norway, all acute psychiatric departments.

Sample: n = 132 patients, aged 18 and over, who fulfil criteria for treatment resistant depression in bipolar disorder, Montgomery Asberg Depression Rating Scale Score of at least 25 at baseline.

Intervention: INTERVENTION group: 3 sessions per week for up to 6 weeks, total up to 18 sessions.

Control group: algorithm-based pharmacological treatment as usual.

Discussion: This study is the first randomized controlled trial that aims to investigate whether electroconvulsive therapy is better than pharmacological treatment as usual in treatment resistant bipolar depression. Possible long lasting cognitive side effects will be evaluated. The study is investigator initiated, without support from industry.

Trial registration: NCT00664976.

Figures

Figure 1
Figure 1
Flow Chart of Study Design.

References

    1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8–19.
    1. Simon GE, Ludman EJ, Bauer MS, Unutzer J, Operskalski B. Long-term effectiveness and cost of a systematic care program for bipolar disorder. Arch Gen Psychiatry. 2006;63(5):500–508. doi: 10.1001/archpsyc.63.5.500.
    1. Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon D, Endicott J, Keller M. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol. 2003;6(2):127–137. doi: 10.1017/S1461145703003341.
    1. Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Rush AJ, Keck PE Jr, McElroy SL, Luckenbaugh DA, Pollio C, Kupka R, Nolen WA. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003;64(6):680–690. quiz 738-689.
    1. Thase ME. Bipolar depression: issues in diagnosis and treatment. Harv Rev Psychiatry. 2005;13(5):257–271. doi: 10.1080/10673220500326425.
    1. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711–1722. doi: 10.1056/NEJMoa064135.
    1. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161(2):217–222. doi: 10.1176/appi.ajp.161.2.217.
    1. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079–1088. doi: 10.1001/archpsyc.60.11.1079.
    1. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351–1360. doi: 10.1176/appi.ajp.162.7.1351.
    1. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4–9. doi: 10.1192/bjp.bp.107.048504.
    1. Hirschfeld RMA, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME, Wagner KD, Perlis RH. American Psychiatric Association: Practice Guidelines for the treatment of patients with bipolar disorder. 2. Washington DC: American Psychiatric Association; 2002.
    1. Moksnes KM, Vatnaland T, Eri B, Torvik NH. Electroconvulsive therapy in the Ullevaal region of Oslo 1988-2002. Tidsskr Nor Laegeforen. 2006;126(13):1750–1753.
    1. Weiner RD, Coffey CE, Fochtmann LJ, Greenberg RM, Isenberg KE, Kellner CH, Sackeim HA, Moench L. The Practice of Electroconvulsive Therapy. Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association. 2. Washington: American Psychiatric Association; 2001.
    1. Sienaert P, Peuskens J. Electroconvulsive therapy: an effective therapy of medication-resistant bipolar disorder. Bipolar Disord. 2006;8(3):304–306. doi: 10.1111/j.1399-5618.2006.00317.x.
    1. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67(Suppl 6):16–22.
    1. Sweeney JA, Kmiec JA, Kupfer DJ. Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery. Biol Psychiatry. 2000;48(7):674–684. doi: 10.1016/S0006-3223(00)00910-0.
    1. Holmes MK, Erickson K, Luckenbaugh DA, Drevets WC, Bain EE, Cannon DM, Snow J, Sahakian BJ, Manji HK, Zarate CA Jr. A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. Bipolar Disord. 2008;10(7):806–815. doi: 10.1111/j.1399-5618.2008.00628.x.
    1. Quraishi S, Frangou S. Neuropsychology of bipolar disorder: a review. J Affect Disord. 2002;72(3):209–226. doi: 10.1016/S0165-0327(02)00091-5.
    1. McCall WV, Reboussin DM, Weiner RD, Sackeim HA. Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry. 2000;57(5):438–444. doi: 10.1001/archpsyc.57.5.438.
    1. Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, Fitzsimons L, Moody BJ, Clark J. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57(5):425–434. doi: 10.1001/archpsyc.57.5.425.
    1. Sackeim HA, Prudic J, Fuller R, Keilp J, Lavori PW, Olfson M. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology. 2007;32(1):244–254. doi: 10.1038/sj.npp.1301180.
    1. Stern Y, Sano M, Pauson J, Mayeux R. Modified Mini-Mental State Examination: validity and reliability. Neurology. 1987;37:179.
    1. National Institute for Clinical Excellence. Guidance on the Use of Electroconvulsive Therapy. London; 2003.
    1. Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med. 2003;35(1):2–11. doi: 10.1080/07853890310004075.
    1. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun. 2003;17(Suppl 1):S119–124. doi: 10.1016/S0889-1591(02)00078-8.
    1. Sinha G. Inflamed brains can trigger the blues, studies suggest. Nat Med. 2004;10(10):1007. doi: 10.1038/nm1004-1007b.
    1. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev. 2005;29(4-5):891–909. doi: 10.1016/j.neubiorev.2005.03.023.
    1. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90(2-3):263–267. doi: 10.1016/j.jad.2005.11.015.
    1. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078–1090. doi: 10.4088/JCP.08r04505.
    1. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: Novel hypothesis-driven treatments for bipolar depression? Neurotoxicology. 2009;30(4):497–521. doi: 10.1016/j.neuro.2009.03.004.
    1. Goodwin FK, Jamison KR. In: Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2. Goodwin FK, Jamison KR, editor. New York: Oxford University Press; 2007. Maintenance Medical Treatment; pp. 797–848.
    1. d'Elia G. Unilateral electroconvulsive therapy. Acta Psychiatr Scand Suppl. 1970;215:1–98.
    1. Abrams R. Electroconvulsive therapy. 4. New York: Oxford University Press; 2002.
    1. d'Elia G. Present Practice of Electroconvulsive Therapy in Scandinavia. Arch Gen Psychiatry. 1983;40:577–581.
    1. Goodwin FK, Jamison KR. In: Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2. Goodwin FK, Jamison KR, editor. New York: Oxford University Press; 2007. Medical Treatment of Depression; pp. 752–753.
    1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33. quiz 34-57.
    1. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID-I/NP) New York: Biometrics Research, New York State Psychiatric Institute; 2002.
    1. Post RM, Nolen WA, Kupka RW, Denicoff KD, Leverich GS, Keck PE Jr, McElroy SL, Rush AJ, Suppes T, Altshuler LL, Frye MA, Grunze H, Walden J. The Stanley Foundation Bipolar Network I. Rationale and Methods. Br J Psychiatry. 2001;178(suppl 41):169–176. doi: 10.1192/bjp.178.41.s169.
    1. Leverich GS, Nolen WA, Rush AJ, McElroy SL, Keck PE, Denicoff KD, Suppes T, Altshuler LL, Kupka R, Kramlinger KG, Post RM. The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. J Affect Disord. 2001;67(1-3):33–44. doi: 10.1016/S0165-0327(01)00430-X.
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389. doi: 10.1192/bjp.134.4.382.
    1. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res. 1986;18(1):65–87. doi: 10.1016/0165-1781(86)90060-0.
    1. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159–171. doi: 10.1016/S0165-1781(97)00123-6.
    1. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435. doi: 10.1192/bjp.133.5.429.
    1. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF) Br J Psychiatry. 1995;166(5):654–659. doi: 10.1192/bjp.166.5.654.
    1. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483. doi: 10.1097/00005650-199206000-00002.
    1. Berns S, Uzelac S, Gonzalez C, Jaeger J. Methodological considerations of measuring disability in bipolar disorder: validity of the Multidimensional Scale of Independent Functioning. Bipolar Disord. 2007;9(1-2):3–10. doi: 10.1111/j.1399-5618.2007.00305.x.
    1. Akiskal HS, Akiskal KK, Haykal RF, Manning JS, Connor PD. TEMPS-A: progress towards validation of a self-rated clinical version of the Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire. J Affect Disord. 2005;85(1-2):3–16. doi: 10.1016/j.jad.2004.12.001.
    1. Low NC, Du Fort GG, Cervantes P. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. Headache. 2003;43(9):940–949. doi: 10.1046/j.1526-4610.2003.03184.x.
    1. Mulder RT, Joyce PR, Frampton C. Relationships among measures of treatment outcome in depressed patients. J Affect Disord. 2003;76(1-3):127–135. doi: 10.1016/S0165-0327(02)00080-0.
    1. Sunderland A, Harri JE, Baddeley AD. Do laboratory tests predict everyday memory? J Verb Learn Verb Behav. 1983;22:341–357. doi: 10.1016/S0022-5371(83)90229-3.
    1. Lingjaerde O, Ahlfors U, Bech P, Dencker S, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100. doi: 10.1111/j.1600-0447.1987.tb10566.x.
    1. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) 2000.
    1. Angst J, Adolfsson R, Benazzi F, Gamma A, Hantouche E, Meyer TD, Skeppar P, Vieta E, Scott J. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord. 2005;88(2):217–233. doi: 10.1016/j.jad.2005.05.011.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅